Media

Media

Recent News

  • Avivagen Inc. to Issue Shares to holders of Debentures in Lieu of Annual Maintenance Fee

    Ottawa, ON /Business Wire/ April 9, 2021/ – Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that a total of 3,931 common shares will be issued at the rate of $0.58 per share to satisfy the maintenance fee of $2,280 owing in respect of the debentures issued on April 9, 2019.   This issuance is …Read More

  • Avivagen Announces Results From Its Annual General Meeting April 8, 2021

    Ottawa, ON / Business Wire / April 8, 2021 / – Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that at the Corporation’s Annual General Meeting (AGM) held today the Corporation’s shareholders voted to support all of the resolutions that came before the meeting.  The resolutions included the reappointment of McGovern Hurley LLP as Avivagen’s …Read More

  • Avivagen Inc. to Issue Shares to holders of Debentures in lieu of Annual Maintenance Fee

    Ottawa, ON /Business Wire/ March 23, 2021/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that it has opted to issue common shares to satisfy $107,560 owing to the holders of 10% secured debentures issued by Avivagen on March 28, 2019 and April 9, 2019 on account of an annual maintenance fee owing to …Read More

  • Avivagen Inc. Announces TSX Venture Exchange Approval for Extension of Warrants

    Ottawa, ON /Business Wire/ March 18, 2021 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture …Read More

  • Avivagen Inc. Announces Stock Option Grants

    Ottawa, ON /Business Wire/ March 8, 2021/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that its Board of Directors has approved the issuance of 577,500 stock options granted to officers, directors, consultants and employees of the Corporation.  The options, which shall be vested over an eight-quarter period, are exercisable up to five years …Read More

View All News Releases

Media Coverage

  • TSX At The Open

    Avivagen CEO Interviewed on C-Suite At The Open

    Kym Anthony, CEO of Avivagen, was recently interviewed by Karoline Hunter, Head of TSX Company Services at the TMX group.

    The interview covered the company story and gives a look ahead at the future of Avivagen’s OxC-BetaTM.

    The interview also covers Immune Priming, its powerful anti-inflammatory effect, and its efficacy in improving Gut Health.

View All Media Coverage